Publications, Pharmaceutical

Developing a Dry Powder Formulation for Aptar Pharma Prohaler®

Aptar Pharma Prohaler® is a novel, high performance, multidose dry powder inhaler device with a patient-centric design developed to promote patient compliance.

This paper describes the optimization of a model formulation for Prohaler® via manipulation of the concentration of fine lactose and the inclusion of a force control agent, to reduce the strength of interparticle forces and promote dose deaggregation. The relationship between formulation composition and dissolution profile was also investigated. The inclusion of a force control agent was shown to be highly beneficial in promoting aerosolization, resulting in a higher fine particle mass and a finer mass median aerodynamic diameter. This effect was robust with respect to lactose fine concentration which in the absence of a force control agent was also observed to correlate positively with fine particle mass. Consideration of the use of force control agents is highly recommended when developing formulations for Prohaler®.

Download Publication
8 May 2021

Learn more about Prohaler®

Find Out More

This Might Also Be of Interest

25 Jun 2020

Confirming bioequivalence for a generic tiotropium dry powder inhalers

Publications, Pharmaceutical, Innovation & Insights, Device Innovations, Product Solutions

Read More
25 Jun 2020

Comparison of Pulmonary Deposition for Single and Multidose Dry Powder Inhalers with ...

Publications, Pharmaceutical, Product Solutions, Innovation & Insights, Device Innovations

Read More
15 Jun 2020

Accelerating the development of COVID vaccines and therapeutics

Webinars, Pharmaceutical, Innovation & Insights, Market Insights, Product Solutions

Read More
15 Jun 2020

Evaluating the Particle Distribution for Dry Powder Inhalers

Publications, Pharmaceutical, Brand Differentiation, Product Solutions, Innovation & Insights

Read More
1 13 14 15 16 17 19
Back To Top